Condition: Retinopathy of Prematurity · Sponsor: University of Zurich
Extremely premature infants are at risk of developing a potentially blinding eye disease, called retinopathy of prematurity (ROP). Currently available treatment, consisting of laser surgery or injection of drugs into the eye balls, may prevent most but not all cases of permanent ROP-mediated blindness. Both types of treatment are associated with significant costs and side effects. An orally administered drug commonly used to treat hypertension, propranolol, may be effective in halting progression of ROP to severe stages, as suggested by preliminary data from small studies. As severe (threshold) ROP is an overall rare disease, the effectiveness of propranolol in combating ROP can only be assessed in a large, multicenter randomized controlled trial involving hospitals caring for extremely preterm infants of diverse origin.
This description comes directly from the study's public registry record.
Dirk Bassler, M.D. · +41 44 255 53 40 · dirk.bassler@usz.ch
Christoph Rüegger, M.D. · +41 43 253 98 10 · christoph.rueegger@usz.ch
Always discuss trial participation with your own doctor first.
| University Hospital Tübingen | Tübingen, Baden-Wurttemberg, Germany | Recruiting |
| University Hospital Zurich | Zurich, Canton of Zurich, Switzerland | Recruiting |
| Ankara University School of Medicine Children's Hospital | Ankara, Ankara, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03083431